Wednesday, Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00.

Across the recent three months, 7 analysts have shared their insights on Absci ABSI, expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of ...

Shares of Absci Co. (NASDAQ:ABSI – Get Free Report) have received a consensus recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports.

Absci (NASDAQ:ABSI – Free Report) had its price objective cut by KeyCorp from $6.00 to $5.00 in a research note released on Wednesday,Benzinga reports.They currently have an overweight rating on ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price target remains the same with $7.00. Discover ...

https://www.tipranks.com/news/the-fly/dentsply-sirona-to-reposition-byte-business-within-aligner-portfolio Absci (ABSI) and Owkin announced a partnership bringing ...

In this article, we are going to take a look at where Absci (NASDAQ:ABSI) stands against other AI companies under $2 billion market cap. It’s clear that AI holds immense promise but it comes ...

This approach allows Absci to quickly advance and monetize clinical-stage assets, aligning well with its AI/ML-driven platform. Price Action: ABSI stock is up 23% at $3.96 at the last check on ...